Clinical trial NCT02398656: A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Official title: Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Stroke, Acute
Keywords: Minor Ischemic Stroke
Lead sponsor: University of Calgary
Sponsor class: OTHER
First posted: 2015-03-25
Enrollment: 1274
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or worsen over the hours or days immediately following a stroke. TEMPO-2 is a minor stroke trial for patients presenting within 12 hours of their symptom onset. Patients will be randomized to TNK-tPA or standard of care. In the intervention group TNK-tPA is given as a single, intravenous bolus (0.25mg/Kg) immediately upon randomization. Maximum dose 50mg. The control group will receive antiplatelet agent(s) as decided by the treating physician. Antiplatelet agent(s) choice will be at the treating physician's discretion.

TEMPO-2 Coordinating Centre is located in Calgary, AB, Canada. There will be approximately 50 sites participating worldwide.

Dr. Shelagh Coutts is the Principal Investigator.

Detailed description: TEMPO2 is an multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care. A total of 1274 patients will be enrolled, at approximately 50 sites worldwide.

TEMPO-2 will enroll patients within a 12 hour time window with a NIHSS score of \<6 and an ASPECTS \>7. All patients will be evaluated clinically and then undergo brain imaging using CT followed immediately by a CT angiogram. Patients must have an intracranial occlusion on CTA or CTP.

Randomization will be 1:1 to TNK-tPA (experimental) or standard of care antiplatelet agents (control).

Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes.

Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. The local investigator to chose which antithrombotic regime should be used

All patients will be treated within 90 minutes of the first slice of the baseline CT. Patients will undergo a study CT angiogram of the intracranial circulation between 4-8 hours after treatment to determine whether the occluded artery has recanalized or not. In sites where MRI/MRA is routinely used this can be substituted for CT/CTA. Any patient who has neurological worsening should have standard of care brain imaging completed to rule out intracranial hemorrhage.

All patients will have standard of care medical management on an acute stroke unit and undergo follow-up imaging at 24 hours with CT or MR. Use of MR will be encouraged.

Patients will be assessed at 24 hours and at Days 5 and 90. The Day 90 Outcomes will be performed by a blinded assessor.

Eligibility criteria: Inclusion Criteria:

1. Acute ischemic stroke in an adult patient (18 years of age or older)
2. Onset (last-seen-well) time to treatment time ≤ 12 hours.
3. TIA or minor stroke defined as a baseline NIHSS ≤ 5 at the time of randomization. Patients do not have to have persistent demonstrable neurological deficit on physical neurological examination.
4. Any acute intracranial occlusion or near occlusion (TICI 0 or 1) (MCA, ACA, PCA, VB territories) defined by non-invasive acute imaging (CT angiography or MR angiography) that is neurologically relevant to the presenting symptoms and signs. Multiphase CTA or CT perfusion are required for this study. An acute occlusion is defined as TICI 0 or TICI 1 flow.1 Practically this can include a small amount of forward flow in the presence of a near occlusion AND, Delayed washout of contrast with pial vessels on multiphase CTA in a region of brain concordant with clinical symptoms and signs OR, Any area of focal perfusion abnormality identified using CT or MR perfusion - e.g. transit delay (TTP, MTT or T Max), in a region of brain concordant with clinical symptoms and signs.
5. Pre-stroke independent functional status - structured mRS ≤2.
6. Informed consent from the patient or surrogate.
7. Patients can be treated within 90 minutes of the first slice of CT or MRI. Scans can be repeated to meet this requirement; if there is no change neurologically then only a CT head need be repeated for assessment of extent and depth of ischemia.

Exclusion Criteria:

1. Hyperdensity on NCCT consistent with intracranial hemorrhage.
2. Large acute stroke ASPECTS \< 7 visible on baseline CT scan.
3. Core of established infarction. No large area (estimated \> 10 cc) of grey matter hypodensity at a similar density to white matter or in the judgment of the enrolling neurologist is consistent with a subacute ischemic stroke \> 12 hours of age.
4. Clinical history, past imaging or clinical judgment suggest that that intracranial occlusion is chronic.
5. Patient has a severe or fatal or disabling illness that will prevent improvement or follow-up or such that the treatment would not likely benefit the patient.
6. Pregnancy
7. Planned thrombolysis with IV tPA or endovascular thrombolysis/thrombectomy treatment.
8. In-hospital stroke unless these patients are at their baseline prior to their stroke. E.g. a patient who had a stroke during a diagnostic coronary angiogram.
9. Commonly accepted exclusions for medical thrombolytic treatment. These are commonly relative contraindications (i.e. the final decision is at the discretion of the treating physician) but for the purposes of TEMPO-2 include the following:

   * International normalized ratio \> 1.7 or known full anticoagulation with use of any standard or direct oral anticoagulant therapy with full anticoagulant dosing. \[DVT prophylaxis dosing shall not prohibit enrolment\]. For low molecular weight heparins (LMWH) more than 48 hours off drug will be considered sufficient to allow trial enrollment. For direct oral anticoagulants; in patients with normal renal function more than 48 hours off drug will be considered sufficient to allow trial enrollment. Patients on direct oral anticoagulants who have any degree of renal impairment should not be enrolled in the trial unless they have not taken a dose of the drug in the last 5 days. Dual antiplatelet therapy does not prohibit enrolment.
   * Dual antiplatelet therapy does not prohibit enrolment. \[For patients who are known not to be taking anticoagulant therapy it is not necessary to wait for coagulation lab results (e.g. PT, PTT) prior to treatment\]
   * Patients who have been acutely treated with GP2b3a inhibitors.
   * Arterial puncture at a non-compressible site in the previous seven days
   * Clinical stroke or serious head or spinal trauma in the preceding three months that would normally preclude use of a thrombolytic agent.
   * History of intracranial hemorrhage, subarachnoid hemorrhage or other brain hemorrhage that would normally preclude use of a thrombolytic agent.
   * Major surgery within the last 3 months at a bodily site where bleeding could result in serious harm or death.
   * Known platelet count below 100,000 per cubic millimeter. Treatment should not be delayed to wait for platelet count unless thrombocytopenia is known or suspected.
   * Gastrointestinal or genitourinary bleeding within the past 3 months that is unresolved or associated with persisting anemia such that thrombolytic treatment of any kind would result in serious bleeding or death.

Primary outcomes:
measure: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS)
timeFrame: 90 Days
Secondary outcomes:
measure: Number of Participants With Modified Rankin Score (mRS) 0-1 at 90 Days
timeFrame: 90 days
Other outcomes:
Locations:
city: Canberra
country: Australia
facility: Calvary Public Hospital Bruce
state: Australian Capital Territory
city: Newcastle
country: Australia
facility: John Hunter Hospital
state: New South Wales
city: Gold Coast
country: Australia
facility: Gold Coast University Hospital
state: Queensland
city: Adelaide
country: Australia
facility: Royal Adelaide Hospital
state: South Australia
city: Box Hill
country: Australia
facility: Box Hill Hospital
state: Victoria
city: Melbourne
country: Australia
facility: Royal Melbourne Hospital
state: Victoria
city: Murdoch
country: Australia
facility: Fiona Stanley Hospital
state: Western Australia
city: Vienna
country: Austria
facility: Medical University of Vienna (Coordinating Centre)
city: Vienna
country: Austria
facility: St. John's of God Hospital Vienna
city: Botucatu
country: Brazil
facility: Hospital de Clínicas de Botucatu
city: Brasília
country: Brazil
facility: Instituto Hospital de Base do Distrito Federal
city: Campo Grande
country: Brazil
facility: Hospital Universitário Maria Aparecida Pedrossian
city: Celso Ramos
country: Brazil
facility: Hospital Celso Ramos Florianopolos
city: Fortaleza
country: Brazil
facility: Hospital Geral de Fortaleza
city: Joinville
country: Brazil
facility: Clinica Neurologica e Neurocirurgica de Joinville Ltda
city: Porto Alegre
country: Brazil
facility: Porto Alegre Hospital
city: Porto Alegre
country: Brazil
facility: Santa Casa de Porto Alegre
city: Ribeirão Preto
country: Brazil
facility: Hospital de Clínicas de Ribeirão Preto
city: Rio De Janeiro
country: Brazil
facility: Americas Medical City
city: São Paulo
country: Brazil
facility: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
city: São Paulo
country: Brazil
facility: Hospital São Paulo UNIFESP
city: São Paulo
country: Brazil
facility: Irmandade Da Santa Casa de Misericordia de Sao Paulo
city: Vitória
country: Brazil
facility: Hospital Estadual Central
city: Calgary
country: Canada
facility: University of Calgary/Foothills Medical Centre
state: Alberta
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
city: New Westminster
country: Canada
facility: Royal Columbian Hospital
state: B.C.
city: Vancouver
country: Canada
facility: Vancouver General Hospital
state: British Columbia
city: Victoria
country: Canada
facility: Victoria General Hospital
state: British Columbia
city: Hamilton
country: Canada
facility: Hamilton Health Sciences Centre
state: Ontario
city: Kingston
country: Canada
facility: Kingston General Hospital
state: Ontario
city: London
country: Canada
facility: London Health Sciences Centre
state: Ontario
city: Ottawa
country: Canada
facility: Ottawa General Hospital
state: Ontario
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
city: Toronto
country: Canada
facility: Sunnybrook Health Sciences Centre
state: Ontario
city: Toronto
country: Canada
facility: Toronto Western
state: Ontario
city: Montreal
country: Canada
facility: McGill University
state: Quebec
city: Quebec City
country: Canada
facility: CHU de Québec-Université Laval
state: Quebec
city: Saskatoon
country: Canada
facility: University of Saskatchewan/ Royal University Hospital
state: Saskatchewan
city: Helsinki
country: Finland
facility: University Central Hospital HUCH
city: Dublin
country: Ireland
facility: Beaumont Hospital
state: Leinster
city: Dublin
country: Ireland
facility: Mater Misericordiae University Hospital Dublin
state: Leinster
city: Christchurch
country: New Zealand
facility: Christchurch Hospital
city: Singapore
country: Singapore
facility: National Neuroscience Institute Tan Tock Seng Hospital
city: Singapore
country: Singapore
facility: Singapore General Hospital
city: A Coruña
country: Spain
facility: Complejo Jospitalario Universitario A Coruna
city: Barcelona
country: Spain
facility: Vall d'Hebron Institut de Recerca (VHIR)
city: Barcelona
country: Spain
facility: Vall d'Hebron Institut de Recerca
city: Girona
country: Spain
facility: Hospital Universitari Doctor Josep Trueta
city: Valladolid
country: Spain
facility: Clinc University Hospital Valladolid
city: London
country: United Kingdom
facility: Countess of Chester
state: England
city: London
country: United Kingdom
facility: St George's University Hospitals NHS Foundation trust
state: England
city: London
country: United Kingdom
facility: Stoke University of North Midlands
state: England
city: London
country: United Kingdom
facility: University College London Hospital
state: England
city: Belfast
country: United Kingdom
facility: Royal Victoria Hospital
state: Northern Ireland
city: Glasgow
country: United Kingdom
facility: Queen Elizabeth University Hospital
state: Scotland
city: Birmingham
country: United Kingdom
facility: Queen Elizabeth Hospital
city: Cambridge
country: United Kingdom
facility: Addenbrooke Hospital
city: London
country: United Kingdom
facility: Charring Cross Hospital
city: London
country: United Kingdom
facility: Kings College Hospital
city: Nottingham
country: United Kingdom
facility: Nottingham University Hospital
city: Oxford
country: United Kingdom
facility: John Radcliffe Hospital
Study officials:
affiliation: University of Calgary
name: Michael D Hill, MD
role: STUDY_DIRECTOR
References:
citation: Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell BCV, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. Lancet. 2024 Jun 15;403(10444):2597-2605. doi: 10.1016/S0140-6736(24)00921-8. Epub 2024 May 17.
citation: Logallo N, Kvistad CE, Thomassen L. Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. CNS Drugs. 2015;29(10):811-8. doi: 10.1007/s40263-015-0280-9.